References
- Hayes A, Batshaw ML. Down syndrome. Pediatr. Clin. North Am.40(3), 523–535 (1993).
- Roper RJ, Reeves RH. Understanding the basis for Down syndrome phenotypes. PLoS Genet.2(3), e50 (2006).
- Contestabile A, Benfenati F, Gasparini L. Communication breaks-down: from neurodevelopment defects to cognitive disabilities in Down syndrome. Prog. Neurobiol.91(1), 1–22 (2010).
- Iannello RC, Crack PJ, de Haan JB et al. Oxidative stress and neural dysfunction in Down syndrome. J. Neural Transm. Suppl.57257–57267 (1999).
- Zana M, Janka Z, Kalman J. Oxidative stress: a bridge between Down’s syndrome and Alzheimer’s disease. Neurobiol. Aging28(5), 648–676 (2007).
- Jovanovic SV, Clements D, MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic. Biol. Med.25(9), 1044–1048 (1998).
- Head E, Lott IT. Down syndrome and β-amyloid deposition. Curr. Opin. Neurol.17(2), 95–100 (2004).
- Butterfield DA, Boyd-Kimball D. Amyloid β-peptide(1–42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol.14(4), 426–432 (2004).
- Butterfield DA, Drake J, Pocernich C et al. Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid β-peptide. Trends Mol. Med.7(12), 548–554 (2001).
- Butterfield DA, Galvan V, Lange MB et al. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid β-peptide of APP. Free Radic. Biol. Med.48(1), 136–144 (2010).
- Odetti P, Angelini G, Dapino D et al. Early glycoxidation damage in brains from Down’s syndrome. Biochem. Biophys. Res. Commun.243(3), 849–851 (1998).
- Nunomura A, Perry G, Pappolla MA et al. Neuronal oxidative stress precedes amyloid-β deposition in Down syndrome. J. Neuropathol. Exp. Neurol.59(11), 1011–1017 (2000).
- Pratico D, Iuliano L, Amerio G et al. Down’s syndrome is associated with increased 8,12-iso-iPF2α-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann. Neurol.48(5), 795–798 (2000).
- Campos C, Guzman R, Lopez-Fernandez E et al. Urinary biomarkers of oxidative/nitrosative stress in healthy smokers. Inhal. Toxicol.23(3), 148–156 (2011).
- Ishihara K, Amano K, Takaki E et al. Increased lipid peroxidation in Down’s syndrome mouse models. J. Neurochem.110(6), 1965–1976 (2009).
- Butterfield DA, Bader Lange ML, Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer’s disease. Biochim. Biophys. Acta.1801(8), 924–929 (2010).
- Reed T, Perluigi M, Sultana R et al. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer’s disease. Neurobiol. Dis.30(1), 107–120 (2008).
- Perluigi M, Sultana R, Cenini G et al. Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer’s disease: role of lipid peroxidation in Alzheimer’s disease pathogenesis. Proteomics Clin. Appl.3(6), 682–693 (2009).
- Perluigi M, di Domenico F, Fiorini A et al. Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Proteomics Clin. Appl.5(3–4), 167–178 (2011).
- Perrone S, Longini M, Bellieni CV et al. Early oxidative stress in amniotic fluid of pregnancies with Down syndrome. Clin. Biochem.40(3–4), 177–180 (2007).